Mankind Pharma was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name ‘Mankind Pharma Private Limited’, pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi (RoC). Pursuant to the conversion of the company to a public limited company and as approved by its shareholders pursuant to a special resolution dated July 14, 2005 the name of the company was changed to ‘Mankind Pharma Limited’ and the RoC issued a fresh certificate of incorporation on April 13, 2006.

The company is India’s fourth largest pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)).It is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has primarily grown organically and are the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in 2022 (Source: IQVIA Dataset, Annual filings / company data). It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and has an established track record of building and scaling brands in-house. It has created many brands in its pharmaceutical business.
 
It is present in several acute and chronic therapeutic areas in India, including anti- infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals /nutrients and respiratory. It entered the consumer healthcare industry in 2007 and has since established several differentiated brands in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories.

Business area of the company

The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Therapeutic Area

• Anti-infectives
• Cardiovascular
• Gastrointestinal
• Vitamins/minerals/nutrients
• Respiratory
• Anti-diabetic
• Dermatology
• Gynaecology
• Pain/analgesics
• Neuro/CNS

Brands of the company

• Nurokind
• Telmikind
• Manforce
• Unwanted
• Moxikind
• Gudcef
• Glimestar
• Amlokind 
• Asthakind
• Dydroboon 
• Prega News
• Candiforce
• Codistar
• Mahacef
• Cefakind 
• Zenflox
• Monticope
• Vomikind
• Caldikind
• Dynaglipt

Awards, accreditations or recognition

• 2007: Emerging Company of the year award at the Pharma Excellence Awards 2007.
  
• 2011: Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
• 2017: Award for Best Design in Healthcare at Healthcare Leadership Awards 2017.
• 2018: Best Condom Brand of the Year award at Sex Brand Awards.
• 2018: Pharma OTC company of the year award at Pharma Excellence Awards 2018.
• 2021: Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for manufacturing.
• 2021: Silver Award for Good Health Brand at IHW Awards 2021.
• 2022: E4m Pride of India - The Best of Bharat Awards 2022 by exchange4media.
• 2022: Award for Branding and Marketing Excellence for the Strategic Initiative to Introduce DMF Quality Drugs in India at National Awards for Leadership & Excellence 2022.
• 2022: EHS Best Practices award at Greentech International EHS Award 2023.
• 2022: Docflix won the Digital Jalebi (DJ Interactive Solutions) award at the Maddies 2022.
• 2022: Best Energy Efficient Case Study (SME Category) at CII National Energy Efficiency Circle Competition by Confederation of Indian Industry.
• 2022: Short film, she can carry both by Prega News won 1st prize at Council for Fair Business Practices Consumer Film Festival.

History and milestones

• 2004: Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets amongst others.
  
• 2005: Set up its first manufacturing facility at Paonta Sahib, Himachal Pradesh.
  
• 2005: Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others.
  
• 2007: Entered the consumer healthcare segment with the launch of ‘Manforce’ brand. 2007: Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst others.
  
• 2007: Raised Rs 72 crore from Monet Limited.
  
• 2009: Set up its manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh.
  
• 2010: Launched ‘Preganews’ brand in the consumer healthcare segment.
  
• 2012: Setup its first R&D centre at IMT Manesar, Haryana.
  
• 2014: Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan).
  
• 2014: Set up its manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh
  
• 2015: Incorporated its Subsidiary, Lifestar Pharma LLC in the US.
  
• 2015: Incorporated its Subsidiary, Mankind Pharma Pte. Limited in Singapore.
  
• 2017: Set up its manufacturing facility in Sikkim.
  
• 2018: Its manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time.
  
• 2019: Entered the female infertility segment with the launch of ‘Dydroboon’ tablets.
  
• 2020: Incorporated its Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal.
  
• 2020: Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets.
  
• 2020: Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets.
  
• 2021: Incorporated its Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE.
  
• 2021: Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets.
  
• 2021: Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets.
  
• 2022: Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited.
  
• 2022: Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others.
  
• 2022: Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others.
  
• 2022: Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories.